Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-MVA Triplex Vaccine in Lymphoma and Multiple Myeloma post-HCT
NCT03383055Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Nov 2018
- Primary completion
- Jul 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Triplex in cytomegalovirus infection (CMV) (2 cohorts), sponsored by Masonic Cancer Center. Primary endpoint: Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) at Day 100. Started Nov 2018; status: completed.
02
Drugs
Triplex
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03383055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383055.